Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open
Bimekizumab was well-tolerated up to 2 years; no new safety signals were identified with longer exposure. Bimekizumab provided deep, durable improvements in clinical and HRQoL outcomes.
Authors
- Haley B. Naik (ORCID: https://orcid.org/0000-0003-2760-3904)
- Christopher J. Sayed (ORCID: https://orcid.org/0000-0003-3201-4637)
- Christos C. Zouboulis (ORCID: https://orcid.org/0000-0003-1646-2608)
- Robert Rolleri
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- T. Vaux
- Delphine Deherder (ORCID: https://orcid.org/0000-0002-7336-1988)
- Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
- Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
- Falk G. Bechara (ORCID: https://orcid.org/0000-0003-0418-521X)
- Georgios Kokolakis (ORCID: https://orcid.org/0000-0002-8042-7885)
- Gregor B. E. Jemec (ORCID: https://orcid.org/0000-0002-0712-2540)
- Bartosz Lukowski (ORCID: https://orcid.org/0009-0008-0217-6313)
- Amit Garg (ORCID: https://orcid.org/0000-0002-4553-9216)
- Akimichi Morita
- Brian Kirby (ORCID: https://orcid.org/0000-0001-9432-8880)
- Christina Crater
Institutions
- Northwell Health (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of California, San Francisco (US)
- North Carolina Institute of Medicine (US)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- Nagoya City University (JP)
- Humboldt-Universität zu Berlin (DE)
- Städtisches Klinikum Dessau (DE)
- UCB Pharma (France) (FR)
- St. Vincent's University Hospital (IE)
- North Shore Diabetes and Endocrine Associates (US)
- St. Josef-Hospital (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Hidradenitis Suppurativa Foundation (US)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jaad.2025.11.031
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Biogen
- Celgene
- CSL Behring
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Torii Pharmaceutical
- Incyte
- Celltrion
- Insmed
- European Commission
- Bundesministerium für Bildung und Forschung
- Eisai
- Kyowa Hakko Kirin
- Mitsubishi Tanabe Pharma Corporation
- Sun Pharma
- Idorsia Pharmaceuticals
- European Academy of Dermatology and Venereology
- InflaRx
- LEO Pharma